Gan & Lee Pharmaceuticals Co., Ltd. (603087.SH) Latest Company News

Oct 15, 2026, 08:44 UTC
El Salvador’s National Directorate of Medicines approved Gan & Lee Pharmaceuticals’ insulin glargine injection (cartridge) for registration, granting it sales authorization in the country.
Source:
- finance.sina.cn
Oct 12, 2026, 08:47 UTC
El Salvador’s National Directorate of Medicines approved Gan & Lee Pharmaceuticals’ registration of its prefilled-pen insulin glargine injection for sale in El Salvador.
Source:
- finance.sina.cn
- finance.sina.cn
Oct 11, 2026, 01:05 UTC
The UK Medicines and Healthcare products Regulatory Agency granted Gan & Lee Pharmaceuticals’ insulin glargine injection marketing authorization for treating diabetes in adults, adolescents and children aged 2 and older.
Source:
- finance.sina.cn
Oct 8, 2026, 08:18 UTC
Gan & Lee Pharmaceuticals announced that its insulin aspart injection received drug registration approval in Ethiopia.
Source:
- finance.sina.cn
Sep 18, 2026, 07:34 UTC
Gan & Lee Pharmaceuticals received approval from China's National Medical Products Administration to conduct clinical trials of its self-developed recombinant human albumin product GLR1075 injection for cirrhotic ascites with hypoalbuminemia.
Source:
- finance.sina.cn
Sep 11, 2026, 19:38 UTC
Gan & Lee Pharmaceuticals reported 2025 revenue above RMB 4 billion and net profit above RMB 1.1 billion, both record highs since its listing, according to CFO Wang Qi.
Source:
- wap.eastmoney.com
Sep 7, 2026, 07:50 UTC
Ganli Pharmaceutical's subsidiary Ganli Pharmaceutical Shandong completed first-patient dosing in a Phase I clinical trial of GZC8072 tablets in China.
Source:
- finance.sina.cn
Aug 25, 2026, 09:09 UTC
Ganli Pharmaceutical announced its 2026 first-half results: revenue of 2.223 billion yuan, up 7.56% year-on-year; net profit attributable to shareholders of 610 million yuan, up 1.01% year-on-year.
Source:
- finance.sina.cn
Aug 24, 2026, 09:04 UTC
Ganlee Pharmaceutical's subsidiary Ganlee Shandong received approval from China's National Medical Products Administration to conduct clinical trials for GZC8072 tablets for weight control.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 12, 2026, 13:50 UTC
Gan & Lee Pharmaceuticals licensed its GLP-1RA biweekly formulation Bofanglutide to Italy's Menarini Group for European commercialization in 39 countries, receiving an upfront payment of 62 million euros and potential milestone payments of 664 million euros.
Source:
Aug 9, 2026, 17:27 UTC
Ganli Pharmaceutical presented 3 self-developed innovative formulations, including Bofanglutide, GZR4 and GZR102, at the 86th American Diabetes Association Scientific Sessions and released the latest clinical research data.
Source:
- wap.eastmoney.com
Aug 6, 2026, 09:53 UTC
Seven directors and senior executives of Gan & Lee Pharmaceuticals plan to reduce their holdings by a total of no more than 840,000 shares through centralized bidding transactions during the period from August 31 to November 30, 2026, accounting for 0.02% of the company's total share capital, for the purpose of repaying personal debts.
Source:
- finance.sina.cn
Jul 9, 2026, 08:59 UTC
Gan & Lee Pharmaceuticals received a drug registration certificate from the Honduras National Drug Regulatory Authority for its insulin glargine injection (prefilled pen) under the brand name VITAGLAR®.
Source:
- finance.sina.cn

603087.SH

El Salvador’s National Directorate of Medicines approved Gan & Lee Pharmaceuticals’ insulin glargine injection (cartridge) for registration, granting it sales authorization in the country.

El Salvador’s National Directorate of Medicines approved Gan & Lee Pharmaceuticals’ registration of its prefilled-pen insulin glargine injection for sale in El Salvador.

The UK Medicines and Healthcare products Regulatory Agency granted Gan & Lee Pharmaceuticals’ insulin glargine injection marketing authorization for treating diabetes in adults, adolescents and children aged 2 and older.

Gan & Lee Pharmaceuticals announced that its insulin aspart injection received drug registration approval in Ethiopia.

Gan & Lee Pharmaceuticals received approval from China's National Medical Products Administration to conduct clinical trials of its self-developed recombinant human albumin product GLR1075 injection for cirrhotic ascites with hypoalbuminemia.

Gan & Lee Pharmaceuticals reported 2025 revenue above RMB 4 billion and net profit above RMB 1.1 billion, both record highs since its listing, according to CFO Wang Qi.

Ganli Pharmaceutical's subsidiary Ganli Pharmaceutical Shandong completed first-patient dosing in a Phase I clinical trial of GZC8072 tablets in China.

Ganli Pharmaceutical announced its 2026 first-half results: revenue of 2.223 billion yuan, up 7.56% year-on-year; net profit attributable to shareholders of 610 million yuan, up 1.01% year-on-year.

Ganlee Pharmaceutical's subsidiary Ganlee Shandong received approval from China's National Medical Products Administration to conduct clinical trials for GZC8072 tablets for weight control.

Gan & Lee Pharmaceuticals licensed its GLP-1RA biweekly formulation Bofanglutide to Italy's Menarini Group for European commercialization in 39 countries, receiving an upfront payment of 62 million euros and potential milestone payments of 664 million euros.

Ganli Pharmaceutical presented 3 self-developed innovative formulations, including Bofanglutide, GZR4 and GZR102, at the 86th American Diabetes Association Scientific Sessions and released the latest clinical research data.

Gan & Lee Pharmaceuticals received a drug registration certificate from the Honduras National Drug Regulatory Authority for its insulin glargine injection (prefilled pen) under the brand name VITAGLAR®.